ONCOLOGY CONTRACT 
MANUFACTURING

At Baxter’s manufacturing facility dedicated to oncology products in Halle/Westfalen, Germany, all of your parenteral needs are handled at one location, enabling processing solutions to fit your compound.

Your oncology products can make a difference in patients’ lives. 

Our oncology manufacturing expertise can help you make that difference.

Global Experience

More than 60 years of oncology experience manufacturing products sold worldwide including North America, South America, Europe and Asia.

Broad Expertise

Dedicated clinical through commercial production with integrated technologies and services. Specialized areas of focus include cytotoxics, highly potent compounds, biologics, lyophilized products, and antibody-drug conjugates (ADCs).

Maximizing Manufacturing Value

Baxter’s Halle facility offers state-of-the-art cGMP manufacturing, uniquely designed to deliver high-quality products with optimum efficiency and speed to market.

To discuss sterile contract manufacturing services for injectable molecules, please contact us at: 
United States: 1-800-4-BAXTER 
International: 1-224-948-4770

Go to article: Home | Antibiotic AdjacentGo to article: In this issueGo to article: ContentsGo to article: SHL Company InsightGo to article: SHL MedicalGo to article: TiveGo to article: Controlant Company InsightGo to article: ControlantGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: L.B. Bohle MaschinenGo to article: L.B Bohle Company InsightGo to article: ACG WorldwideGo to article: CommentGo to article: HPV infections drop due to widespread vaccinationGo to article: Europe reports the highest prevalence of chronic cough across the 7MMGo to article: How could vaccine hesitancy affect the prevalence of hearing disorders?Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: RegPakGo to article: PfeifferGo to article: In DepthGo to article: Antibiotic adjacent: the alternatives tackling AMR Go to article: Regenerative medicine: ready for the big leagues? Go to article: Human challenge trials: pandemic exit strategy or ethical nightmare?Go to article: Drug dispensing goes digitalGo to article: Could this Novartis initiative finally cure sickle cell disease?Go to article: Centessa Pharmaceuticals: forging a new path for pharma R&DGo to article: Biomax Company InsightGo to article: BiomaxGo to article: DuojectGo to article: Duoject Company InsightGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: MyonexGo to article: BaxterGo to article: EventsGo to article: Next issue